Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01101334 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: CS-7017
DRUG: erlotinib

Sponsor

Daiichi Sankyo